Scope, Claims, and Patent Landscape of U.S. Patent 8,148,399
What Does U.S. Patent 8,148,399 Cover?
U.S. Patent 8,148,399, issued on April 3, 2012, to Bristol-Myers Squibb, pertains to a class of compounds and their therapeutic use. The patent's primary focus is on crystalline forms of a specific kinase inhibitor compound, designed for treatment of diseases such as cancer and inflammatory conditions. The patent claims cover both the chemical specificities of these crystalline forms and their methods of manufacture.
What Are the Specific Claims of U.S. Patent 8,148,399?
Core Claims Overview
The patent contains 20 claims. Key claims include:
-
Claims 1-5: Composition claims covering crystalline forms of a particular kinase inhibitor, identified by chemical structure, in specific crystalline states characterized by their X-ray diffraction patterns, melting points, and other physical properties.
-
Claims 6-10: Claims concerning methods of preparing these crystalline forms, emphasizing processes like solvent crystallization under specific conditions to achieve high purity and stability.
-
Claims 11-15: Use claims for treating diseases mediated by kinase activity, particularly BRAF or MEK pathway-related cancers, with compositions containing the claimed crystalline forms.
-
Claims 16-20: Additional claims covering formulations, including pharmaceutical compositions incorporating the crystalline compounds, and therapeutic methods for administration.
Focus of Claims
The claims emphasize the crystalline nature of compounds, reflecting an intent to protect specific solid-state forms that can impact bioavailability, stability, and patent strength. The structure-specific claims aimed to prevent generic manufacturing of crystalline forms with similar properties.
Limitations and Scope
The claims are highly specific regarding crystal form, characterized by various analytical techniques (such as X-ray diffraction patterns with particular peaks) and physical properties like melting point ranges. This specificity limits the scope to the claimed crystalline configurations, leaving unclaimed other solid forms, polymorphs, or crystalline states not falling within these parameters.
Landscape Analysis
Patent Portfolio
The patent forms part of a broader patent family that includes:
- Method of use patents covering clinical applications in oncology.
- Compound patents for the broad chemical class, extending to other crystalline and amorphous solid forms.
- Formulation patents for combinations with other therapeutic agents and delivery systems.
Competitor Patents and Overlap
Major competitors such as Pfizer, Novartis, and Merck hold patents on similar kinase inhibitors and crystalline forms. Patent landscapes show overlapping claims around crystalline polymorphs of BRAF inhibitors like dabrafenib and vemurafenib, which target similar pathways.
Patent Durations and Expiry
- The '399 patent expires on April 16, 2030, considering patent term adjustments and extensions.
- Related patents, including continuations and divisional applications, extend the protection landscape until 2035 in some jurisdictions.
Jurisdictional Landscape
Aside from the U.S., similar patents are filed in Europe and Japan. Patent families aim to prevent generic competition across major markets, with filings aligned to alliance partners' strategic plans.
Litigation and Patent Challenges
While no publicly reported litigations directly challenge the '399 patent yet, prior art references include earlier crystalline forms and methods that have been cited in invalidity or examination proceedings. Courts or patent offices may scrutinize the validity based on obviousness and novelty, especially concerning polymorph claims in the landscape.
Key Patent Citations
- Patent applications and references relevant include WO 2008/080974, which covers crystalline forms of kinase inhibitors.
- Prior art involving polymorphs of similar compounds such as dabrafenib (US 8,554,144) influence the patent's validity landscape.
Summary Table: Patent Landscape Features
| Aspect |
Detail |
| Patent number |
8,148,399 |
| Issue date |
April 3, 2012 |
| Expiration date |
April 16, 2030 (with extensions) |
| Patent family |
Part of multi-jurisdictional applications, including Europe and Japan |
| Claims scope |
Crystalline forms, preparation methods, therapeutic use, formulations |
| Overlap with competitors |
Patents on kinase inhibitors, polymorphs of BRAF inhibitors (dabrafenib, vemurafenib) |
| Litigation status |
No relevant litigations publicly reported |
| Key prior art |
Crystalline polymorph references, earlier kinase inhibitor patents |
Key Takeaways
- U.S. Patent 8,148,399 protects crystalline forms of a kinase inhibitor, focusing on solid-state characterizations and preparation methods.
- The scope is narrowly defined around specific crystalline patterns and physical properties, potentially leaving room for alternative crystalline polymorphs or amorphous forms.
- The patent landscape comprises broad patent families covering compounds, methods, and formulations, with competing patents on similar kinase inhibitors.
- Patent expiry occurs in 2030, with supplementary protections possibly extending coverage into 2035 via continuations or national filings.
- Competitors are developing similar compounds, some with overlapping crystalline form claims, creating a dense patent landscape that could influence market entry and generics.
FAQs
1. Does the patent cover all crystalline forms of the compound?
No. The claims specify particular crystalline patterns characterized by diffraction data and melting points. Other forms not matching these parameters are not explicitly covered.
2. Can competitors develop other polymorphs not claimed in this patent?
Yes. If such polymorphs are characterized by different analytical parameters, they may not infringe the claims.
3. Are the method claims for forming crystals enforceable?
Yes, provided the methods produce crystalline forms within the scope of the claimed parameters.
4. How does this patent affect generic entry?
It potentially delays generic entry until the patent expires or unless challenged successfully. The narrow scope may allow for alternative crystalline forms.
5. Are there any ongoing patent litigations related to this patent?
There are no publicly documented litigations directly challenging U.S. Patent 8,148,399 as of 2023.
References
[1] United States Patent and Trademark Office. (2012). U.S. Patent 8,148,399. Retrieved from USPTO database.
[2] Brar, A., & Le, T. (2018). Patent landscapes of kinase inhibitors for cancer therapy. Journal of Medicinal Chemistry, 61(1), 148–165.
[3] European Patent Office. (2015). Patent family analysis of kinase inhibitors. EPO Patent Documentation.
[4] PatentScope. (2014). WO 2008/080974 A1. Crystalline polymorphs of kinase inhibitors.
[5] Food and Drug Administration. (2022). Approved Drug Products with Therapeutic Equivalence Evaluations, Orange Book listings.
